PRODUCT INFORMATION

Diroximel Fumarate

Item No. 29111

CAS Registry No.:	1577222-14-0
Formal Name:	(2E)-butenedioic acid, 1-[2-(2,5-dioxo-1-pyrrolidinyl)ethyl] 4-methyl ester
Synonym:	BIIB098
MF:	$C_{11}H_{13}NO_6$
FW:	255.2
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Diroximel fumarate is supplied as a solid. A stock solution may be made by dissolving the diroximel fumarate in the solvent of choice, which should be purged with an inert gas. Diroximel fumarate is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of diroximel fumarate in these solvents is approximately 10 mg/ml.

Diroximel fumarate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, diroximel fumarate should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Diroximel fumarate has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Diroximel fumarate is a prodrug form of monomethyl fumarate (Item No. 27813).[1] It undergoes esterase cleavage in the gut to release monomethyl fumarate. Formulations containing diroximel fumarate have been used in the treatment of relapsing-remitting multiple sclerosis.

Reference

1. Naismith, R.T., Wolinsky, J.S., Wundes, A., *et al.* Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. *Mult. Scler.* (2019).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM